dihydroartemisinin
E718725
active pharmaceutical ingredient
antimalarial drug
endoperoxide-containing sesquiterpene lactone
semisynthetic derivative of artemisinin
Dihydroartemisinin is a potent antimalarial drug derived from artemisinin, widely used as a key component of artemisinin-based combination therapies to treat Plasmodium falciparum malaria.
Statements (49)
| Predicate | Object |
|---|---|
| instanceOf |
active pharmaceutical ingredient
ⓘ
antimalarial drug ⓘ endoperoxide-containing sesquiterpene lactone ⓘ semisynthetic derivative of artemisinin ⓘ |
| componentOf |
artemisinin-based combination therapy
ⓘ
dihydroartemisinin–piperaquine combination ⓘ dihydroartemisinin–piperaquine–trimethoprim combination ⓘ |
| derivedFrom | artemisinin ⓘ |
| developedInCountry | China NERFINISHED ⓘ |
| discoveredAsDrugIn | 1970s ⓘ |
| eliminationRoute |
hepatic metabolism
ⓘ
renal excretion of metabolites ⓘ |
| hasATCCode | P01BE06 ⓘ |
| hasBioavailability | high oral bioavailability ⓘ |
| hasCASNumber | 71939-50-9 ⓘ |
| hasChEBIID | CHEBI:94685 ⓘ |
| hasChemicalClass |
artemisinin derivatives
ⓘ
sesquiterpene lactones ⓘ |
| hasCommonAdverseEffect |
abdominal pain
ⓘ
dizziness ⓘ headache ⓘ nausea ⓘ vomiting ⓘ |
| hasFunctionalGroup |
endoperoxide bridge
ⓘ
lactone ⓘ secondary alcohol ⓘ |
| hasHalfLife | approximately 1–3 hours in humans ⓘ |
| hasIUPACName | (3R,5aS,6R,8aS,9R,10S,12R,12aR)-Decahydro-3,6,9-trimethyl-3,12-epoxy-12H-pyrano[4,3-j]-1,2-benzodioxepin-10-ol ⓘ |
| hasMechanismOfAction |
disrupts parasite proteins via endoperoxide bridge cleavage
ⓘ
generates reactive oxygen species in Plasmodium parasites ⓘ |
| hasMeltingPoint | approximately 152–157 °C ⓘ |
| hasMolarMass | 284.35 g/mol ⓘ |
| hasMolecularFormula | C15H24O5 ⓘ |
| hasPregnancyCategory | use with caution in first trimester ⓘ |
| hasProteinBinding | moderate protein binding ⓘ |
| hasPubChemCID | 456410 ⓘ |
| hasRouteOfAdministration |
intramuscular
ⓘ
intravenous ⓘ oral ⓘ rectal ⓘ |
| hasUNII | K848JZ4886 ⓘ |
| hasWHOModelListStatus | included in WHO Model List of Essential Medicines (via combinations) ⓘ |
| metaboliteOf |
artemether
ⓘ
artesunate ⓘ |
| targetsOrganism |
Plasmodium falciparum
NERFINISHED
ⓘ
Plasmodium vivax NERFINISHED ⓘ |
| usedForTreatmentOf |
Plasmodium falciparum malaria
ⓘ
severe malaria ⓘ uncomplicated malaria ⓘ |
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.